Digital Biomarkers Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.64 Billion |
| Market Size (2029) | USD 9.02 Billion |
| CAGR (2024 - 2029) | 19.90 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Digital Biomarkers Market Analysis
The Digital Biomarkers Market size is estimated at USD 3.64 billion in 2024, and is expected to reach USD 9.02 billion by 2029, growing at a CAGR of 19.90% during the forecast period (2024-2029).
The major factors driving market growth include the growing number of clinical trials and technological advancements in digital biomarkers.
The increasing prevalence of chronic diseases in developing countries and developed countries is anticipated to support the use of digital biomarkers for remote patient monitoring. According to the Centers for Disease Control and Prevention, the percentage of coronary heart disease for adults aged 18 and over in the United States was 4.9% in 2022.
Moreover, market players' introduction of innovative and easy-to-use wearables and software to detect various vital signs is augmenting the demand for digital biomarkers. For instance, in November 2022, Shimmer Research launched its Verisense Digital Health Panel (DHP) to provide clinical researchers with unprocessed, real-world sensor data, enhancing their insights.
The sensor data will be integrated with patient-reported outcomes and various real-world sources, such as tokenized medical records, claims, and pharmacy data. This will facilitate the development of standardized digital biomarkers and endpoints, enhancing confidence and trust among regulators, payors, and patients, thereby boosting market growth.
The increasing number of clinical trials, the growth in research investments, and the development of various therapeutics to manage chronic conditions are expected to drive the demand for digital tools, including digital biomarkers. According to clinicaltrials.gov, 20,189 clinical trials were active in June 2024. The large number of ongoing clinical trials is accountable for the surge in demand for digital biomarkers.
Therefore, owing to the factors mentioned above, the market is anticipated to witness growth over the forecast period. However, high product costs and data security concerns are expected to hinder market growth.
Digital Biomarkers Market Trends
The Monitoring Digital Biomarkers Segment is Anticipated to Witness Significant Growth Over the Forecast Period
The segment for monitoring digital biomarkers accounts for a significant market share, and it is likely to record prominent growth during the forecast period.
Monitoring digital biomarkers are primarily used to monitor the vital signs of patients suffering from various chronic diseases, including cardiovascular and metabolic disorders, respiratory disorders, etc. The growing prevalence of chronic diseases is expected to drive the demand for monitoring digital biosensors in the near future.
According to a report published by the Centers for Disease Control and Prevention in April 2024, the percentage of adults diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic bronchitis was 4.6% in 2022. Such a high prevalence of respiratory diseases in developed countries is anticipated to increase the demand for monitoring digital biomarkers to access pulmonary functions, driving the segment's growth.
The developments and introductions of innovative products in this segment are also important factors expected to increase the adoption of monitoring digital biomarkers in the forecast period. For instance, in September 2022, Nutromics secured USD 14 million funding from Dexcom Ventures for the development of a platform 'lab-in-a-patch' that uses DNA sensor technology to track multiple targets in the human body, including disease biomarkers and hard-to-dose drugs. Thus, the increasing number of new product launches is anticipated to drive the demand for effective digital biomarkers in the near future.
Therefore, the monitoring digital biosensors segment is expected to witness significant growth over the forecast period owing to the increase in the prevalence of chronic diseases and the introduction of innovative products to the market.
North America is Expected to Hold a Major Share in the Digital Biomarkers Market
North America is expected to hold a significant share of the market owing to factors such as the rising prevalence of chronic diseases, the growing number of clinical trials in the United States, and the availability of technologically advanced products in the region.
According to the report published by the Centers for Disease Control and Prevention in July 2024, the percentage of heart attacks for adults aged 18 and over in the United States was 1.6% in 2022. As cardiac digital biomarkers help in the assessment of cardiac functions in heart failure, the market is anticipated to grow over the forecast period.
Additionally, according to the clinicaltrials.gov, as of July 2024, 2,139 clinical trials were active in Canada. Thus, the large number of ongoing clinical trials in Canada is anticipated to increase the adoption of digital biomarkers for real-time health monitoring in patients, supporting market growth in the region.
Also, increasing technological advancements by market players and the presence of key players in the region are responsible for driving demand for digital biomarkers. For instance, in February 2022, ActiGraph launched CPIW 2.0 for the continuous tracking of real-world movement and sleep behaviors in clinical trial participants.
Therefore, factors such as the large number of ongoing clinical trials and rising initiatives from the key market players are anticipated to boost market growth over the forecast period
Digital Biomarkers Industry Overview
The digital biomarkers market is semi-consolidated in nature due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Major market players include Akili Inc., ActiGraph LLC, AliveCor Inc., Fitbit Health Solutions, Empatica Inc., Biogen, F. Hoffmann-La Roche Ltd, Koneksa, IXICO PLC, and Huma.
Digital Biomarkers Market Leaders
-
ActiGraph
-
Fitbit Health Solutions
-
Biogen
-
F. Hoffmann-La Roche Ltd.
-
Huma
*Disclaimer: Major Players sorted in no particular order
Digital Biomarkers Market News
- April 2024: Indivi, a Swiss medical technology company, partnered with Biogen to enhance a digital biomarker platform for an upcoming clinical trial of BIIB122, a novel treatment for Parkinson's disease. Under the agreement, Biogen will license its smartphone-based platform, Konectom, to the Swiss company.
- March 2024: Koneksa, a key player in evidence-based digital biomarkers for healthcare, partnered with Merck to join its Data Syndication Partnership program for the LEARNS observational study. This study aims to develop digital biomarkers for neurodegenerative disorders using smartphone-based assessments and wearable technologies.
Digital Biomarkers Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Chronic Diseases
- 4.2.2 Growing Number of Clinical Trials
- 4.2.3 Technological Advancements in Digital Biomarkers
-
4.3 Market Restraints
- 4.3.1 High Product Cost
- 4.3.2 Data Security Concerns
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Data Collection Tools
- 5.1.2 Data Integration Tools
-
5.2 By Clinical Practice
- 5.2.1 Monitoring Digital Biomarkers
- 5.2.2 Diagnostic Digital Biomarkers
- 5.2.3 Predictive and Prognostic Digital Biomarkers
- 5.2.4 Others
-
5.3 By Therapeutic Area
- 5.3.1 Cardiovascular and Metabolic Disorders
- 5.3.2 Respiratory Disorders
- 5.3.3 Neurological Disorders
- 5.3.4 Musculoskeletal Disorders
- 5.3.5 Others
-
5.4 By End User
- 5.4.1 Pharmaceutical Companies
- 5.4.2 Healthcare Providers
- 5.4.3 Payers
- 5.4.4 Others
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Akili Inc.
- 6.1.2 ActiGraph LLC
- 6.1.3 AliveCor Inc.
- 6.1.4 Fitbit Health Solutions
- 6.1.5 Empatica Inc.
- 6.1.6 Biogen
- 6.1.7 F. Hoffmann-La Roche Ltd
- 6.1.8 Koneksa
- 6.1.9 IXICO PLC
- 6.1.10 Huma
- 6.1.11 Empatica Inc.
- 6.1.12 ALTOIDA AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDigital Biomarkers Industry Segmentation
Digital biomarkers are digital devices such as portables, wearables, implantables, or digestibles used to collect objective, quantifiable physiological and behavioral data. The data collected is used mainly to understand health-related outcomes.
The digital biomarkers market is segmented by type, clinical practice, therapeutic area, end user, and geography. By type, the market is segmented into data collection tools and data integration tools. By clinical practice, the market is segmented into monitoring digital biomarkers, diagnostic digital biomarkers, predictive and prognostic digital biomarkers, and other clinical practices. By therapeutic area, the market is segmented into cardiovascular and metabolic disorders, respiratory disorders, neurological disorders, musculoskeletal disorders, and other therapeutic areas. By end user, the market is segmented into pharmaceutical companies, healthcare providers, payers, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the values (USD) for all the above segments.
| By Type | Data Collection Tools | |
| Data Integration Tools | ||
| By Clinical Practice | Monitoring Digital Biomarkers | |
| Diagnostic Digital Biomarkers | ||
| Predictive and Prognostic Digital Biomarkers | ||
| Others | ||
| By Therapeutic Area | Cardiovascular and Metabolic Disorders | |
| Respiratory Disorders | ||
| Neurological Disorders | ||
| Musculoskeletal Disorders | ||
| Others | ||
| By End User | Pharmaceutical Companies | |
| Healthcare Providers | ||
| Payers | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Digital Biomarkers Market Research FAQs
How big is the Digital Biomarkers Market?
The Digital Biomarkers Market size is expected to reach USD 3.64 billion in 2024 and grow at a CAGR of 19.90% to reach USD 9.02 billion by 2029.
What is the current Digital Biomarkers Market size?
In 2024, the Digital Biomarkers Market size is expected to reach USD 3.64 billion.
Who are the key players in Digital Biomarkers Market?
ActiGraph, Fitbit Health Solutions, Biogen, F. Hoffmann-La Roche Ltd. and Huma are the major companies operating in the Digital Biomarkers Market.
Which is the fastest growing region in Digital Biomarkers Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Digital Biomarkers Market?
In 2024, the North America accounts for the largest market share in Digital Biomarkers Market.
What years does this Digital Biomarkers Market cover, and what was the market size in 2023?
In 2023, the Digital Biomarkers Market size was estimated at USD 2.92 billion. The report covers the Digital Biomarkers Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Digital Biomarkers Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Digital Biomarkers Industry Report
Statistics for the 2024 Digital Biomarkers market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Digital Biomarkers analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
